1,742 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Capital Advisors Wealth Management LLC

Capital Advisors Wealth Management LLC purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,742 shares of the pharmaceutical company’s stock, valued at approximately $728,000.

A number of other hedge funds also recently bought and sold shares of the company. University of Texas Texas AM Investment Managment Co. purchased a new position in Vertex Pharmaceuticals in the 4th quarter worth about $25,000. Arlington Trust Co LLC increased its position in shares of Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares during the last quarter. ICA Group Wealth Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $28,000. Fortitude Family Office LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $30,000. Finally, Baystate Wealth Management LLC increased its position in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Activity

In other news, EVP Ourania Tatsis sold 2,350 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $439.11, for a total transaction of $1,031,908.50. Following the transaction, the executive vice president now owns 53,523 shares in the company, valued at $23,502,484.53. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Bruce I. Sachs sold 7,073 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total value of $3,168,704.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $17,920,000. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Ourania Tatsis sold 2,350 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $439.11, for a total transaction of $1,031,908.50. Following the completion of the transaction, the executive vice president now owns 53,523 shares in the company, valued at approximately $23,502,484.53. The disclosure for this sale can be found here. Insiders have sold a total of 26,086 shares of company stock worth $11,983,266 over the last 90 days. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 0.1 %

Vertex Pharmaceuticals stock traded up $0.68 during trading hours on Tuesday, reaching $475.63. The stock had a trading volume of 242,255 shares, compared to its average volume of 1,221,047. The company has a market cap of $122.74 billion, a price-to-earnings ratio of 30.82, a PEG ratio of 2.39 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. The business’s 50 day moving average price is $438.61 and its 200-day moving average price is $423.84. Vertex Pharmaceuticals Incorporated has a 52 week low of $335.82 and a 52 week high of $486.42.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last announced its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business had revenue of $2.69 billion during the quarter, compared to the consensus estimate of $2.58 billion. During the same period in the previous year, the company posted $2.67 earnings per share. The firm’s revenue was up 13.3% on a year-over-year basis. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.32 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on VRTX shares. Guggenheim upped their price target on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. Oppenheimer reissued an “outperform” rating and issued a $500.00 target price on shares of Vertex Pharmaceuticals in a report on Monday, April 15th. Piper Sandler increased their target price on shares of Vertex Pharmaceuticals from $450.00 to $456.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. UBS Group dropped their price target on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Finally, Argus upped their price target on Vertex Pharmaceuticals from $465.00 to $550.00 and gave the stock a “buy” rating in a research note on Monday, June 17th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $444.23.

Check Out Our Latest Analysis on Vertex Pharmaceuticals

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

See Also

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.